Latest Breaking News On - Duchenne cardiomyopathy - Page 1 : comparemela.com

IPS HEART Receives U S FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease

IPS HEART Receives U S FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Stephanie carringtonRauf ashrafDrug administrationRare pediatric drug designationOrphan drug designationChief executive officerDuchenne cardiomyopathy

IPS HEART Receives U S FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treat

Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidateHOUSTON (BUSINESS WIRE) IPS HEART, a privately held cell therapy company advancing its stem cell platform to develop new skeletal muscle and cardiac muscle generation treatments for Duchenne muscular dystrophy (a rare disease) and hea.

Rauf ashrafStephanie carringtonDrug administrationRare pediatric drug designationOrphan drug designationChief executive officerDuchenne cardiomyopathy

IPS HEART receives FDA Rare Pediatric Drug Designations for both of its Stem Cell Drugs for Duchenne

HOUSTON (BUSINESS WIRE) IPS HEART has been granted rare pediatric drug designation by the FDA for GIVI-MPC, a first-in-class stem cell therapeutic to create new skeletal muscle with 100% full length dystrophin and for ISX9-CPC, a first-in-class stem cell therapeutic for creating new functional cardiac muscle for t.

Rauf ashrafDuchenne muscular dystrophyDuchenne cardiomyopathyRejection fraction